Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 41

recruiting
3 968
countries
28
conditions
2 103

607 trials match your criteria

Long-Term Safety Study of GT005 for Patients with Geographic Atrophy Due to Age-Related Macular Degeneration Previously Treated in a Gyroscope Study

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gt005

Study of IO102-IO103 and Pembrolizumab for Patients with Advanced Melanoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Io102 Hydrochloride

Biliary neoplasm+1

Not recruiting

Study on Rilvegostomig and Chemotherapy for Patients with Biliary Tract Cancer After Surgery

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Neurofibromatosis

Not recruiting

Study on Selumetinib for Children Aged 1 to 6 with Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Selumetinib

Study of LY3541860 and Meglumine Gadoterate for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Ly3541860

Study on the Safety and Effectiveness of Padeliporfin Therapy for Patients with Low-Grade Upper Tract Urothelial Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Padeliporfin

Uveal melanoma+2

Not recruiting

Study on the Effectiveness and Safety of Belzupacap Sarotalocan for Patients with Small Choroidal Melanoma or Indeterminate Lesions

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Belzupacap Sarotalocan

Neurofibromatosis+1

Not recruiting

Study on Selumetinib for Adults with Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Selumetinib

Malignant melanoma+4

Not recruiting

Study on the Effectiveness and Safety of RO7198457 and Pembrolizumab for Patients with Untreated Advanced Melanoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Autogene Cevumeran

Corneal dystrophy

Not recruiting

Study on the Safety and Effectiveness of Ripasudil Eye Drops for Patients with Fuchs Endothelial Corneal Dystrophy After Descemetorhexis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ripasudil

Dermatitis atopic

Not recruiting

Study on Amlitelimab for Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis Using Topical Corticosteroids and Inadequate Response to Previous Treatments

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab

Study of daxdilimab injection for adults with moderate to severe discoid lupus erythematosus

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Daxdilimab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.